Human tissue-derived iPS (induced pluripotent stem) cardiomyocytes and hepatocytes present molecular and physiological features very similar to native cardiac or hepato-cells, making them more functionally relevant for research and screening efforts. However, the high cost of iPS cells limits their use with high-content screening assays.
The Curiox DropArray™ platform reduces the amount of cells needed for screening assays by 3-10X, providing a cost-effective pathway for use of iPS cells with high-content cellular assays. This is accomplished via gentle, low velocity liquid exchange during assay procedures that allows iPS cells to be retained. Compared to conventional 384-well microplates that need 5000-7500 cells per well, 384-well DropArray Microplates only require 900-1500 cells per well.